Aberrant DNA Methylation in Ovarian Cancer
- 1 March 2003
- journal article
- Published by Wiley in Annals of the New York Academy of Sciences
- Vol. 983 (1) , 243-250
- https://doi.org/10.1111/j.1749-6632.2003.tb05979.x
Abstract
Abstract: Epigenetic regulation of gene expression has been observed in a variety of tumor types. We have used microarray technology to evaluate the predisposition of drug response by aberrant methylation in ovarian cancer. Results indicate that loss of gene activity due to hypermethylation potentially confers a predisposition in certain cancer types and is an early event in disease progression. Methylation profiles of ovarian cancer might be useful for early cancer detection and prediction of chemotherapy outcome in a clinical context.Keywords
This publication has 15 references indexed in Scilit:
- Use of CpG island microarrays to identify colorectal tumors with a high degree of concurrent methylationMethods, 2002
- Methylation mattersJournal of Medical Genetics, 2001
- Vitamin D and cancer: effects of 1,25(OH)2D3 and its analogs on growth control and tumorigenesisFrontiers in Bioscience-Landmark, 2001
- Cancer Statistics, 2001CA: A Cancer Journal for Clinicians, 2001
- Regional methylation of the 5' end CpG island of BRCA1 is associated with reduced gene expression in human somatic cellsThe FASEB Journal, 2000
- A role for methylation of the hMLH1 promoter in loss of hMLH1 expression and drug resistance in ovarian cancerOncogene, 1999
- Drug resistance in ovarian cancer: from the laboratory to the clinicObstetrics & Gynecology, 1998
- Chemotherapy resistance in ovarian cancer: New molecular perspectivesPublished by Wolters Kluwer Health ,1998
- hMLH1 expression and cellular responses of ovarian tumour cells to treatment with cytotoxic anticancer agentsOncogene, 1997
- Cisplatin and Adriamycin Resistance Are Associated with MutLα and Mismatch Repair Deficiency in an Ovarian Tumor Cell LineJournal of Biological Chemistry, 1996